Results of Operations and Financial Condition. On August 10, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2026 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and s…

Director — Brian C. Thomas, Ph.D.: Dr. Thomas resigned from his position as a member of the Board.

Results of Operations and Financial Condition. On May 11, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and sha…

Results of Operations and Financial Condition. On March 5, 2026, Metagenomi Therapeutics, Inc. (the “Company”) announced its financial results for the year ended December 31, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and sh…

Results of Operations and Financial Condition. On November 11, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and shall n…

Entry into a Material Definitive Agreement. On September 29, 2025 (the “Effective Date”), Metagenomi, Inc. (the “Company”) entered into a Non-Exclusive License Agreement (the “Acuitas License Agreement”) with Acuitas Therapeutics, Inc. (“Acuitas”) pursuant to which Acuitas granted the Company a non-exclusive license to certain Acuitas lipid nanoparticle (“LNP”) technology, including LNP patents, formulation processes, and analytical characterization methods for manufacturing products that inc…

Termination of a Material Definitive Agreement. On September 30, 2025 (the “Termination Date”), the Company delivered to Affini-T Therapeutics, Inc. (“Affini-T”) a notice to terminate the Development, Option and License Agreement dated June 14, 2022 (the “Affini-T License Agreement”) by and between the Company and Affini-T (the “Termination”), effective immediately, due to Affini-T’s making of an assignment for the benefit of creditors, as permitted pursuant to Section 12.2.3 of the Affini-T…

Results of Operations and Financial Condition. On August 12, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02 (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 18…

Results of Operations and Financial Condition. On May 13, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2025 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpose…

or 7.01 of Form 8-K or to provide disclosure pursuant to

Results of Operations and Financial Condition. On March 17, 2025, Metagenomi, Inc. (the “Company”) announced its financial results for the year ended December 31, 2024 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpo…

Director — Eric Bjerkholt: The board of directors appointed Eric Bjerkholt as a new director.

Results of Operations and Financial Condition. On November 13, 2024, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2024 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” fo…

Results of Operations and Financial Condition. On August 14, 2024, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2024 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpo…

Results of Operations and Financial Condition. On May 14, 2024, Metagenomi, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purpose…

Results of Operations and Financial Condition. Although it has not finalized its full financial results for the quarter ended March 31, 2024, the Company expects to report that it had approximately $327.4 million in cash and cash equivalents as of March 31, 2024. This estimate is unaudited and preliminary and does not present all information necessary for an understanding of the Company’s financial condition as of March 31, 2024, and its results of operations for the quarter ended March 31, 2…

Termination of a Material Definitive Agreement. On April 26, 2024 (the “Termination Date”), Metagenomi, Inc. (the “Company”) and ModernaTX, Inc. (“Moderna”) mutually terminated the Strategic Collaboration and License Agreement dated October 29, 2021 (the “Collaboration Agreement”) by and between the Company and Moderna. The Collaboration Agreement was terminated pursuant to a Mutual Termination Agreement (the “Termination Agreement”), dated as of April 26, 2024, by and between the Company and…

Results of Operations and Financial Condition. On March 27, 2024, Metagenomi, Inc. announced its financial results for the year ended December 31, 2023 and additional business updates. A copy of the press release in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed “filed” for purposes of Section 1…